EICHORPublic-registry site landscape for NCT01888081, “A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma”, a Melanoma study sponsored by Virogen Biotechnology Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT01888081 (registry record) |
| Study title | A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma |
| Official title | Phase I/II Trial of A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for the Treatment of Stage IV Melanoma |
| Sponsor | Virogen Biotechnology Inc. |
| Condition(s) | Melanoma |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 1 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT01888081.
Eichor generates a preliminary site-risk snapshot for NCT01888081 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Melanoma trials
← Eichor home · All tracked trials · Melanoma studies · Weekly briefs
